v3.26.1
Consolidated Statements of Operations and Comprehensive Loss (Details)
 12 Months Ended
Feb. 01, 2025
EUR (€)
Dec. 31, 2025
EUR (€)
€ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
EUR (€)
€ / shares
shares
Dec. 31, 2024
$ / shares
Dec. 31, 2023
EUR (€)
€ / shares
shares
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Revenue   € 29,331   € 165,789   € 63,089
Cost of sales   7,267,618   3,317,039   532,262
Inventory write downs   3,300,000   7,300,000    
Marketing and sales expenses, decreased   2,300,000        
Marketing and sales expenses   4,482,011   6,756,595   4,001,299
Other expenses   1,600,000   3,800,000    
Legal and consulting fees   1,000,000   2,500,000    
Other expense items   600,000        
Legal fees       1,400,000    
Restructuring expenses   0.2        
General and administrative expenses   500,000        
Income expenses   2,600,000   5,100,000   13,200,000
Net financial result   4,300,000        
Gain financial net   2,600,000        
Financial result   2,637,922   € 6,949,680   € 2,240,566
Foreign exchange   8,500,000        
Marketable securities   € 1,400,000        
Weighted number of ordinary shares outstanding (in Shares) | shares   67,288,321 67,288,321 58,919,958   54,940,137
Loss per share (in Euro per share) | € / shares   € 0.68   € 0.78   € 0.78
Exercise price for options outstanding (in Euro per share) | € / shares   0.01   0.01    
Weighted average fair value options granted | (per share)   € 2.13 $ 2.41 € 1.65 $ 1.78  
Options granted   2,452,000 2,452,000 2,332,500   1,735,750
Options were exercised       12,000   31,000
Options were forfeited   98,876 98,876     105,327
Expected dividends (in Dollars) | $          
Cost of sales [member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Cost of sales   € 4,000,000        
2017 [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Conversion rate | € / shares   € 0.8511   € 0.9626    
Average rate | € / shares   € 0.8855   € 0.9242    
Weighted average remaining contractual life   6 years 6 months 18 days 6 years 6 months 18 days 6 years 6 months    
Maximum number of common shares available for grant (in Shares) | shares   2,341,097 2,341,097      
Ordinary shares percentage   4.00% 4.00%      
2016 Plan [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Weighted average remaining contractual life   5 years 11 months 4 days 5 years 11 months 4 days 6 years 11 months 4 days    
Minimum [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Exercise price range | (per share)   € 1.29 $ 1.51 € 1.45 1.51  
Maximum [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Exercise price range | (per share)   € 4.37 5.14 € 4.95 5.14  
InflaRx GmbH [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Revenue   € 0   € 200,000   € 100,000
Conversion rate | $ / shares     0.8511   0.9626  
Average rate | $ / shares     $ 0.8855   $ 0.9242  
Executive Management [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Options granted   1,300,000 1,300,000 1,300,000   1,136,000
Options were exercised   136,250 136,250      
Marketing and Sales Expenses [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Marketing and sales expenses   € 4,500,000   € 6,800,000    
Personnel costs   2,000,000   1,800,000    
External services for distribution   200,000   2,000,000    
Marketing Expenses [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Marketing expenses   1,500,000   1,600,000    
Pre-Funded Warrants [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Fair value gain € 5,700,000          
Research and Developments Expense [Member]            
Consolidated Statements of Operations and Comprehensive Loss [Line Items]            
Increased research and development expense   € 9,600,000   € 7,200,000